Hemangiol

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

propranolol hidroklorid

Available from:

Pierre Fabre Medicament

ATC code:

C07AA05

INN (International Name):

propranolol

Therapeutic group:

Beta blokatorji

Therapeutic area:

Hemangioma

Therapeutic indications:

Hemangiol is indicated in the treatment of proliferating infantile haemangioma requiring systemic therapy: , Life- or function-threatening haemangioma,, Ulcerated haemangioma with pain and/or lack of response to simple wound care measures,, Haemangioma with a risk of permanent scars or disfigurement. , It is to be initiated in infants aged 5 weeks to 5 months.

Product summary:

Revision: 6

Authorization status:

Pooblaščeni

Authorization date:

2014-04-23

Patient Information leaflet

                                20
9.
POSEBNA NAVODILA ZA SHRANJEVANJE
Steklenico shranjujte v škatli za zagotovitev zaščite pred
svetlobo.
Po vsaki uporabi skupaj shranite steklenico in peroralno brizgo v
škatlo.
Ne zamrzujte.
10.
POSEBNI
VARNOSTNI
UKREPI
ZA
ODSTRANJEVANJE
NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
PIERRE FABE MEDICAMENT
Les Cauquillous
81500 Lavaur
12.
ŠTEVILKA
(ŠTEVILKE)
DOVOLJENJA
(DOVOLJENJ)
ZA
PROMET
Z
ZDRAVILOM
EU/1/14/919/001
13.
ŠTEVILKA SERIJE
_ _
Lot
14.
NAČIN IZDAJANJA ZDRAVILA
_ _
_ _
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
HEMANGIOL
17.
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA KODA
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
18.
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI
PC: {številka}
SN: {številka}
NN: {številka}
21
B. NAVODILO ZA UPORABO
22
NAVODILO ZA UPORABO
HEMANGIOL 3,75 MG/ML PERORALNA RAZTOPINA
propranolol
PRED ZAČETKOM UPORABE ZDRAVILA NATANČNO PREBERITE NAVODILO, KER
VSEBUJE ZA VAS POMEMBNE
PODATKE!
•
Navodilo shranite. Morda ga boste želeli ponovno prebrati.
•
Če imate dodatna vprašanja, se posvetujte z zdravnikom, farmacevtom
ali medicinsko sestro.
•
Zdravilo je bilo predpisano vašemu otroku in ga ne smete dajati
drugim. Njim bi lahko celo
škodovalo, čeprav imajo znake bolezni, podobne znakom vašega
otroka.
•
Če opazite kateri koli neželeni učinek, se posvetujte z zdravnikom,
farmacevtom ali medicinsko
sestro. Posvetujte se tudi, če opazite katere koli neželene učinke,
ki niso navedeni v tem
navodilu. Glejte poglavje 4.
KAJ VSEBUJE NAVODILO
1.
Kaj je zdravilo HEMANGIOL in za kaj ga uporabljamo
2.
Kaj morate vedeti, preden vaš otrok prejme zdravilo HEMANGIOL
3.
Kako otroku dajati zdravilo HEMANGIOL
4.
Možni neželeni učinki
5.
Shranjevanje zdravila HEMANGIOL
6.
Vsebina pakiranja in dodatne informacije
1
KAJ JE ZDRAVILO HEMANGIOL IN ZA KAJ GA UPORABLJAMO
KAJ JE ZDRAVILO HEMANGIOL
Vaše zdravilo se imenuje HEMANGIOL. Učinkovina je propranolol.
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1
IME ZDRAVILA
HEMANGIOL 3,75 mg/ml peroralna raztopina
2
KAKOVOSTNA IN KOLIČINSKA SESTAVA
1 ml raztopine vsebuje 4,28 mg propranololijevega klorida, kar ustreza
3,75 mg propranolola.
Pomožne snovi z znanim učinkom:
1 ml raztopine vsebuje
propilenglikol………………………………………………….2,60
mg
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3
FARMACEVTSKA OBLIKA
peroralna raztopina
Prozorna, brezbarvna do rahlo rumena peroralna raztopina s sadnim
vonjem.
4
KLINIČNI PODATKI
4.1
TERAPEVTSKE INDIKACIJE
Zdravilo HEMANGIOL
je indicirano za zdravljenje hitro rastočega infantilnega hemangioma,
ki zahteva sistematično
zdravljenje:
•
hemangiom, ki ogroža življenje ali telesne funkcije,
•
ulceriran hemangiom, ki ga spremlja bolečina in/ali pomanjkanje
odzivnosti na enostavne ukrepe
pri oskrbi rane,
•
hemangiom s tveganjem trajnih brazgotin ali izmaličenja.
Zdravilo je indicirano pri dojenčkih, starih od 5 tednov do 5 mesecev
(glejte poglavje 4.2).
4.2
ODMERJANJE IN NAČIN UPORABE
_ _
Zdravljenje z zdravilom HEMANGIOL smejo uvesti zdravniki, ki so
izkušeni pri diagnosticiranju,
zdravljenju in oskrbi infantilnega hemangioma, v nadzorovanem
bolnišničnem okolju, kjer je na voljo
dovolj ustrezne opreme za obravnavo neželenih reakcij, vključno s
tistimi, ki zahtevajo takojšnje
ukrepanje.
_ _
Odmerjanje
Odmerjanje je izraženo v količini propranolola.
Priporočen začetni odmerek je 1 mg/kg/dan, ki je razdeljen na dva
ločena odmerka po 0,5 mg/kg.
Priporočamo povečanje odmerka do terapevtskega odmerka pod
zdravniškim nadzorom kot sledi:
1 teden 1 mg/kg/dan, nato 1 teden 2 mg/kg/dan in nato 3 mg/kg/dan kot
vzdrževalni odmerek.
Terapevtski odmerek je 3 mg/kg/dan, ki ga je treba dajati v 2 ločenih
odmerkih po 1,5 mg/kg, enega
zjutraj in drugega pozno popoldan, med obema vnosoma pa mora miniti
vsaj 9 ur. Zdravilo
HEMANGIOL je treba vzeti med obrokom ali takoj po njem, da se
prepreči tveganje hipoglikemije.
Če otrok ne je
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 09-02-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 09-02-2023
Public Assessment Report Public Assessment Report Bulgarian 19-05-2014
Patient Information leaflet Patient Information leaflet Spanish 09-02-2023
Public Assessment Report Public Assessment Report Spanish 19-05-2014
Patient Information leaflet Patient Information leaflet Czech 09-02-2023
Public Assessment Report Public Assessment Report Czech 19-05-2014
Patient Information leaflet Patient Information leaflet Danish 09-02-2023
Public Assessment Report Public Assessment Report Danish 19-05-2014
Patient Information leaflet Patient Information leaflet German 09-02-2023
Public Assessment Report Public Assessment Report German 19-05-2014
Patient Information leaflet Patient Information leaflet Estonian 09-02-2023
Public Assessment Report Public Assessment Report Estonian 19-05-2014
Patient Information leaflet Patient Information leaflet Greek 09-02-2023
Public Assessment Report Public Assessment Report Greek 19-05-2014
Patient Information leaflet Patient Information leaflet English 09-02-2023
Public Assessment Report Public Assessment Report English 19-05-2014
Patient Information leaflet Patient Information leaflet French 09-02-2023
Public Assessment Report Public Assessment Report French 19-05-2014
Patient Information leaflet Patient Information leaflet Italian 09-02-2023
Public Assessment Report Public Assessment Report Italian 19-05-2014
Patient Information leaflet Patient Information leaflet Latvian 09-02-2023
Public Assessment Report Public Assessment Report Latvian 19-05-2014
Patient Information leaflet Patient Information leaflet Lithuanian 09-02-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 09-02-2023
Public Assessment Report Public Assessment Report Lithuanian 19-05-2014
Patient Information leaflet Patient Information leaflet Hungarian 09-02-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 09-02-2023
Public Assessment Report Public Assessment Report Hungarian 19-05-2014
Patient Information leaflet Patient Information leaflet Maltese 09-02-2023
Public Assessment Report Public Assessment Report Maltese 19-05-2014
Patient Information leaflet Patient Information leaflet Dutch 09-02-2023
Public Assessment Report Public Assessment Report Dutch 19-05-2014
Patient Information leaflet Patient Information leaflet Polish 09-02-2023
Public Assessment Report Public Assessment Report Polish 19-05-2014
Patient Information leaflet Patient Information leaflet Portuguese 09-02-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 09-02-2023
Public Assessment Report Public Assessment Report Portuguese 19-05-2014
Patient Information leaflet Patient Information leaflet Romanian 09-02-2023
Public Assessment Report Public Assessment Report Romanian 19-05-2014
Patient Information leaflet Patient Information leaflet Slovak 09-02-2023
Public Assessment Report Public Assessment Report Slovak 19-05-2014
Patient Information leaflet Patient Information leaflet Finnish 09-02-2023
Public Assessment Report Public Assessment Report Finnish 19-05-2014
Patient Information leaflet Patient Information leaflet Swedish 09-02-2023
Public Assessment Report Public Assessment Report Swedish 19-05-2014
Patient Information leaflet Patient Information leaflet Norwegian 09-02-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 09-02-2023
Patient Information leaflet Patient Information leaflet Icelandic 09-02-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 09-02-2023
Patient Information leaflet Patient Information leaflet Croatian 09-02-2023
Public Assessment Report Public Assessment Report Croatian 19-05-2014

Search alerts related to this product

View documents history